The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.
Study Type
OBSERVATIONAL
Enrollment
26
OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
Unnamed facility
Antwerp, Belgium
Time to OZURDEX® Re-Injection in the Study Eye
The time interval is measured from the first OZURDEX® injection to the second OZURDEX® injection in the study eye.
Time frame: Up to 12 Months
Change From Baseline in Best Corrected Visual Acuity (BCVA) 7 to 12 Weeks Following Last Injection in the Study Eye
BCVA is measured in the study eye following each injection of OZURDEX® using a special eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the number of letters read correctly, the better the vision (or visual acuity). A positive number improvement in the number of letters read means that the vision has improved. Data are reported for the 7-12 week period following the last injection.
Time frame: Baseline, 7 to 12 weeks following the last injection
Percentage of Patients With an Increase of 2 Lines or More in BCVA From Baseline in the Study Eye
BCVA following the first injection of OZURDEX® is measured in the study eye using a special eye chart and is reported as the number of lines (5 letters per line) read correctly. An increase of 2 lines or more indicates an improvement.
Time frame: Baseline, Up to 12 Months
Percentage of Patients With an Increase of 3 Lines or More in BCVA From Baseline in the Study Eye
BCVA following the first injection of OZURDEX® is measured in the study eye using a special eye chart and is reported as the number of lines (5 letters per line) read correctly. An increase of 3 lines or more indicates an improvement.
Time frame: Baseline, Up to 12 Months
Change From Baseline in Central Retinal Thickness in the Study Eye by Optical Coherence Tomography (OCT) 7 to 12 Weeks Following Last Injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
OCT is measured in the study eye following each injection of OZURDEX®. OCT is a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina to assess retinal thickness. A negative change indicates an improvement. Data are reported for the 7-12 week period following the last injection.
Time frame: Baseline, 7 to 12 weeks following the last injection
Time to Improvement of 2 Lines or More in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA following the first injection of OZURDEX® is measured in the study eye using a special eye chart and is reported as the number of lines (5 letters per line) read correctly. An increase of 2 lines or more indicates an improvement.
Time frame: Baseline, Up to 12 Months
Time to Improvement of 3 Lines or More in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA following the first injection of OZURDEX® is measured in the study eye using a special eye chart and is reported as the number of lines (5 letters per line) read correctly. An increase of 3 lines or more indicates an improvement.
Time frame: Baseline, Up to 12 Months